The Safety and Efficacy of Ondansetron in Reducing Immune Checkpoint Inhibitor-Related Toxicities
First Affiliated Hospital of Wenzhou Medical University
First Affiliated Hospital of Wenzhou Medical University
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
Sichuan Cancer Hospital and Research Institute
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
University of Michigan Rogel Cancer Center
Alliance for Clinical Trials in Oncology
National Institutes of Health Clinical Center (CC)
Alliance for Clinical Trials in Oncology
The First Affiliated Hospital of Zhengzhou University
Australasian Leukaemia and Lymphoma Group
Sun Yat-sen University
Immune Oncology Research Institute
Ipsen
Duke University
Ente Ospedaliero Cantonale, Bellinzona
M.D. Anderson Cancer Center
Umeå University
University of Oklahoma
ChineseAMS
Canadian Cancer Trials Group
Henlix, Inc
Merck Sharp & Dohme LLC
Instituto Nacional de Cancerologia de Mexico
Duke University
GlaxoSmithKline
Merck Sharp & Dohme LLC
GlaxoSmithKline
University of Washington
Fred Hutchinson Cancer Center
OHSU Knight Cancer Institute
H. Lee Moffitt Cancer Center and Research Institute
Ottawa Hospital Research Institute
All India Institute of Medical Sciences
Sanofi
Alliance for Clinical Trials in Oncology
University of Rochester
University of Rochester
M.D. Anderson Cancer Center
GlaxoSmithKline
Università Vita-Salute San Raffaele
Duke University
University of Manitoba
Ohio State University Comprehensive Cancer Center
University of Oklahoma
M.D. Anderson Cancer Center
Washington University School of Medicine
University of Rochester
Hallym University Medical Center